DEFINIUM THERAPEUTICS RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR DT120 (LYSERGIDE) ORALLY DISINTEGRATING TABLET (ODT) IN MAJOR DEPRESSIVE DISORDER (MDD) FOLLOWING POSITIVE PHASE 3 RESULTS

Reuters · 1d ago

Please log in to view news